If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Technetium-99m's short half-life of 6 hours makes long-term storage impossible. Transport of 99mTc from the limited number of production sites to radio pharmacies (for manufacture of specific radiopharmaceuticals) and other end users would be complicated by the need to significantly overproduce to have sufficient remaining activity after long journeys. Instead, the longer-lived parent nuclide 99Mo can be supplied to radio pharmacies in a generator, after its extraction from the neutron-irradiated uranium targets and its purification in dedicated processing facilities. Radio pharmacies may be hospital-based or stand-alone facilities, and in many cases will subsequently distribute 99mTc radiopharmaceuticals to regional nuclear medicine departments. Development in direct production of 99mTc, without first producing the parent 99Mo, precludes the use of generators; however, this is uncommon and relies on suitable production facilities close to radio pharmacies.
Alpha particles were first described in the investigations of radioactivity by Ernest Rutherford in 1899, and by 1907 they were identified as He2+ ions. By 1928, George Gamow had solved the theory of alpha decay via tunneling. The alpha particle is trapped inside the nucleus by an attractive nuclear potential well and a repulsive electromagnetic potential barrier. Classically, it is forbidden to escape, but according to the (then) newly discovered principles of quantum mechanics, it has a tiny (but non-zero) probability of "tunneling" through the barrier and appearing on the other side to escape the nucleus. Gamow solved a model potential for the nucleus and derived, from first principles, a relationship between the half-life of the decay, and the energy of the emission, which had been previously discovered empirically and was known as the Geiger–Nuttall law.
=== 21st century === In 2007, the 500th store opened in Seattle, Washington, and in 2010, the 1,000th opened in Beaverton, Oregon. As of March 2017, Jimmy John's had almost 3,000 stores with plans for expansion up to 5,000 and beyond. Liautaud realized that, in order to grow, he would need help acquiring better locations for his stores. Since he had little expertise in real estate, he decided to take on a partner who did. In January 2007, Liautaud sold a 33% stake to Weston Presidio, a San Francisco–based private-equity firm. In the first year after partnering with Weston Presidio, 100 real estate deals were closed. The company has completed two recapitalizations since Weston Presidio's investment. In the summer of 2015, pictures of Liautaud posing with big game circulated on social media, leading to increased calls to boycott his restaurants. In a 2015 interview with the Chicago Tribune, Liautaud said, "I don't hunt big African game anymore." In September 2016, Jimmy John's announced that Roark Capital Group had agreed to acquire a majority stake in the company. Terms of the transaction were not immediately disclosed, though it was later clarified that Liautaud retained 35% ownership of the company as part of the deal. As part of the agreement, Liautaud would continue as chairman of the board. On September 25, 2019, Inspire Brands (affiliated with Roark Capital Group) announced that it was buying Jimmy John's for an unspecified amount in a deal unanimously approved by Liautaud and the rest of the Jimmy John's board of directors.
=== Conversion of malic into lactic === Lactic acid bacteria convert malic acid into lactic acid as an indirect means of creating energy for the bacteria by chemiosmosis which uses the difference in pH gradient between inside the cell and outside in the wine to produce ATP. One model on how this is accomplished notes that the form of L-malate most present at the low pH of wine is its negatively charged monoanionic form. When the bacteria move this anion from the wine into higher pH level of its cellular plasma membrane, it causes a net-negative charge that creates electrical potential. The decarboxylation of malate into L-lactic acid releases not only carbon dioxide but also consumes a proton, which generates the pH gradient which can produce ATP. Lactic acid bacteria convert L-malic acid found naturally in wine grapes. Most commercial malic acid additives are a mixture of the enantiomers D+ and L-malic acid.
Corey Taylor − vocals, guitar on track 17, additional guitar on tracks 4, 8 and 12 James Root − guitar (on all tracks except 18), drums on track 15 Josh Rand − guitar (on all tracks except 18) Shawn Economaki − bass (on all tracks except 17 and 18) Roy Mayorga − drums (on all tracks except 1, 15, 17 and 18) Additional personnel
Sources: en.wikipedia.org
== Development and release == Garry's Mod was created by the programmer Garry Newman. He started developing games under the studio name Facepunch Studios after dropping out of college, at the time out of his parents' house. He did this as a hobby, simultaneous to his occupation as a PHP programmer for a dating website. He was later fired when he launched his own dating website. While developing his first game, Facewound, Garry's Mod became a side-project of his as a mod for the Source game engine and, principally, the game Half-Life 2. Newman soon found more enjoyment in developing Garry's Mod than in maintaining Facewound, so development on Facewound was mostly halted (and put on indefinite hiatus in 2004) for him to focus on Garry's Mod. He stated that, at the time, his skills in computer programming were not advanced enough to create a full Source-based game and he resorted to the mod format. The first iteration of the mod, version 1, was released on 24 December 2004. Initial feedback was polarised, with some players criticising the mod for its similarity to an existing mod, JBMod. However, the increasing positive reception led Newman to continue development. Newman did not recognise that the game was gaining in popularity until he set up an online forum for it. Through 2004 and 2005, Newman released several updated versions of Garry's Mod, adding new features and culminating in version 9.0.4 on 27 November 2005. Newman began work on remaking the mod into a standalone game with assistance from community members.
Ag+O2− + H2C=CH2 → (CH2CH2)O + AgO The resulting silver oxide then oxidizes ethylene or ethylene oxide to CO2 and water. This reaction replenishes the silver catalyst. Thus the overall reaction is expressed as
Naftali Loewenthal, member of the Chabad Hasidic community; main area of study is Hasidism and Jewish Mysticism; professor in the Department of Hebrew and Jewish Studies at University College London; director of the Chabad Research Unit, a division of the Chabad-Lubavitch movement in United Kingdom; author of Communicating the Infinite: The Emergence of the Habad School (1990); also authored Hasidism Beyond Modernity: Essays in Habad Thought and History (2019) as well as many scholarly articles and publications on the Chabad mysticism; also extensively written on history of Chabad Hasidic women. Nick Lowles, founder of Hope Not Hate and former editor of the anti-fascist Searchlight (magazine), backed by various politicians and celebrities several trade unions. Knowles is the author of a number of books on football violence, right wing groups and antisemitism in Britain. He was a freelance investigative journalist, working in television, including on BBC Panorama, World in Action, Channel Four Dispatches and MacIntyre Undercover. Moshé Machover (Hebrew: משה מחובר; born 1936) is a mathematician, philosopher, pro Palestinian socialist anti-Zionist activist and author, noted for his writings critical of Israel and Zionism. David Magarshack (23 December 1899 – 26 October 1977); author, translator and biographer of Russian authors, best remembered for his translations of Dostoevsky, Chekhov and Nikolai Gogol; of Russian Jewish ancestry. Miriam Margolyes (born 18 May 1941) is a British and Australian actress.
== Background == In Canada, clinical chemists work as members of the medical laboratory management team, which consists of pathologists, laboratory managers, and senior technologists. They are primarily responsible for setting the standards of performance for the clinical biochemistry laboratory. The knowledge they acquired from post doctoral training programs is applied to maintain efficiency in the lab.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.